PositiveID to Exhibit its Caregiver Non-Contact Thermometer at the American Association of Critical-Care Nurses Exposition May 23-25

Caregiver can save users $250 or more per year per device in probe cover supplies


DELRAY BEACH, Fla., May 08, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (OTCQB:PSID), a Life Sciences Company focused on detection and diagnostics, announced today that its Thermomedics subsidiary will exhibit the Caregiver® non-contact thermometer at the American Association of Critical-Care Nurses (AACN) National Teaching Institute and Critical Care Exposition from May 23-25 at the George R. Brown Convention Center in Houston, TX.

Caregiver, which is FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers, which are as much as $0.05 to $0.10 per temperature, storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.

PositiveID’s Thermomedics team is exhibiting at the AACN conference to increase exposure and awareness for Caregiver and generate qualified leads for its national network of distributors.

The AACN Critical Care Exposition is the largest, most comprehensive trade show for acute and critical care nurses, advanced practice nurses, clinical nurse specialists, nurse practitioners and nurse managers as well as progressive care, transport and emergency department nurses who treat critically ill patients. AACN's audience is estimated at approximately 7,000 influential nurses.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics Company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

SAFE HARBOR

Statements about PositiveID's future expectations, including the likelihood that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market; the Company’s ability to attract and retain new customers; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on November 18, 2016, August 12, 2016, and May 16, 2016, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


            

Kontaktdaten